Fair Value Measurements
The following tables show our cash, cash equivalents and marketable securities at fair value as of March 31, 2026 and 2025 (in thousands):
March 31, 2026
Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Cash and money market funds$30,789 $— $— $30,789 
Marketable securities
U.S. treasury securities— 14,614 — 14,614 
Total$30,789 $14,614 $— $45,403 
March 31, 2025
Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Cash and money market funds$67,131 $— $— $67,131 
Marketable securities
U.S. treasury securities— 13,351 — 13,351 
Total$67,131 $13,351 $— $80,482 
The carrying amounts of our prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short term nature. We had no financial liabilities measured at fair value on a recurring basis at March 31, 2026 or 2025. There were no transfers between Levels 1, 2 or 3 for any of the periods presented.
Our marketable securities consist solely of U.S. Treasury notes, for which the expected credit loss is considered to be zero. Accordingly, no allowance for credit losses has been recorded on our available-for-sale debt securities as of March 31, 2026 or 2025.
The following table summarizes our marketable securities as of March 31, 2026 and 2025 (in thousands):

March 31, 2026
Maturity (in years)Amortized CostUnrealized GainsUnrealized LossesFair Value
U.S. treasury notesLess than 1$14,616 $$(4)$14,614 
Total$14,616 $$(4)$14,614 

March 31, 2025
Maturity (in years)Amortized CostUnrealized GainsUnrealized LossesFair Value
U.S. treasury notesLess than 1$13,346 $$— $13,351 
Total$13,346 $$— $13,351 
Free Sentinel

Want the next Vistagen Therapeutics, Inc. fair value disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment Vistagen Therapeutics, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

Historical Timeline

Fiscal YearFiled
2026Jun 15, 2026Showing above
2025Jun 17, 2025
2024Jun 11, 2024
2017Jun 29, 2017
2016Jun 24, 2016

About Fair Value Disclosures

Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.

Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.